Cervomed reports first quarter 2024 financial results and provides corporate updates

- cervomed on track to complete enrollment in 2q 2024 in its rewind-lb phase 2b clinical trial evaluating neflamapimod in patients with dementia with lewy bodies (dlb); topline data expected in 4q 2024-

CRVO Ratings Summary

CRVO Quant Ranking